Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens

Infection Control and Hospital Epidemiology

Volumn 18, Issue 5, 1997, Pages 316-321

  VanCouwenberghe, Carolyn J ^a,b,c   Farver, Thomas B ^b   Cohen, Stuart H ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; COMMUNICABLE DISEASE; CONFIDENCE INTERVAL; CROSS INFECTION; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; RESPIRATORY TRACT DISEASE; RISK; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL MODEL; TIME; UNITED STATES; URINE; XANTHOMONAS;

ADULT; ANTI-BACTERIAL AGENTS; CALIFORNIA; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMMUNITY-ACQUIRED INFECTIONS; CONFIDENCE INTERVALS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INTUBATION, INTRATRACHEAL; LOGISTIC MODELS; MALE; MATCHED-PAIR ANALYSIS; MULTIVARIATE ANALYSIS; ODDS RATIO; RESPIRATORY TRACT DISEASES; RISK FACTORS; TIME FACTORS; XANTHOMONAS;

EID: 0031136588     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141224     Document Type: Article

References (26)

1. Swartz MN. Hospital-acquired infections: diseases with increasing limited therapies. Proc Natt Acad Sci USA 1994;91:2420-2427.
2. Palleroni NJ, Bradbury JF. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia. Int J Syst Bacteriol 1993;43:606-609.
3. VanCouwenberghe CJ, Cohen SH. Analysis of epidemic and endemic isolates of Xanthomonas maltophilia by contour-clamped homogeneous electric field gel electrophoresis. Infect Control Hosp Epidemiol 1994;15:691-696.
4. VanCouwenberghe CJ, Cohen SH, Tang YJ, Gumerlock PH, Silva J Jr. Genomic fingerprinting of epidemic and endemic strains of Stenotrophomonas (formerly Xanthomonas maltophilia) by arbitrarily primed PCR. J Clin Microbiol 1995;33:1289-1291.
5. Aoun M, Van der Auwera P, Devleeshouwer C, et al. Bacteraemia caused by non-aeruginosa Pseudomonas species in a cancer center. J Hosp Infect 1992;22:307-316.
6. Victor M, Arpi M, Bruun B, Jønsson V, Hansen M. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 1994;26:163-170.
7. Nagai T. Association of Pseudomonas maltophilia with malignant lesions. J. Clin Microbiol 1984;20:1003-1005.
8. Khardori N, Elting L, Wong E, Schable B, Bodey G. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990;12:997-1003.
9. Noskin G, Grohmann S. Xanthomonas maltophilia bacteremia: an analysis of factors influencing outcome. Infectious Diseases in Clinical Practice 1992;1:230-236.
10. Kerr KG, Corps CM, Hawkey PM. Infections due to Xanthomonas maltophilia in patients with hematologic malignancy. Rev Infect Dis 1991;13:762.
11. Elting L, Bodey G._Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine 1990;69:296-306.
12. Elting L, Khardori N, Bodey G, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990;11:134-138.
13. Garner J, Jarvis W, Emori T, Horan T, Hughes J. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-140.
14. Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
15. Pollack M, Ruttiman U, Getson P. Pediatric Risk of Mortality (PRISM) score. Crit Care Med 1988;16:1110-1116.
16. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992;13:201-206.
17. Hulisz D, File T. Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. Infect Control Hosp Epidemiol 1992;13:489-490.
18. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994;38:624-627.
19. Morrison A, Hoffmann K, Wenzel R. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986;24:52-55.
20. Garcia-Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Munoz Bellido JL. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of β-Lactam/β-Lactamase inhibitor combinations. Diagn Microbiol Infect Dis 1991;14:239-243.
21. Rolston K, Anaissie E, Bodey G. In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents. J Antimicrob Chemother 1987;19:193-196.
22. Jang T, Wang F, Wang L, Liu C, Liu I. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992;91:1170-1176.
23. Winston D, Ho W, Bruckner D, Champlin R. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 1991;115:849-859.
24. McDonald GR, Pernenkil R. Community-acquired Xanthomonas maltophilia pyelonephritis. South Med J 1993;86:967-968.
25. Roilides E, Butler KM, Husson RN, Mueller BU, Lewis LL, Pizzo PA. Pseudomonas infections in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1992;11:547-553,
26. Laing FPY, Ramotar K, Read RR, et al. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995;33:513-518.